Market closed
Protalix BioTherapeutics/$PLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protalix BioTherapeutics
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Ticker
$PLX
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
213
Website
PLX Metrics
BasicAdvanced
$203M
70.94
$0.04
0.72
-
Price and volume
Market cap
$203M
Beta
0.72
52-week high
$2.76
52-week low
$0.82
Average daily volume
696K
Financial strength
Current ratio
2.345
Quick ratio
1.473
Long term debt to equity
9.317
Total debt to equity
12.788
Interest coverage (TTM)
3.69%
Management effectiveness
Return on assets (TTM)
3.10%
Return on equity (TTM)
7.64%
Valuation
Price to earnings (TTM)
70.936
Price to revenue (TTM)
3.532
Price to book
4.56
Price to tangible book (TTM)
4.56
Price to free cash flow (TTM)
25.511
Growth
Revenue change (TTM)
-18.47%
Earnings per share change (TTM)
-53.85%
3-year revenue growth (CAGR)
11.67%
3-year earnings per share growth (CAGR)
-60.00%
What the Analysts think about PLX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Protalix BioTherapeutics stock.
PLX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PLX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PLX News
AllArticlesVideos
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMI
Proactive Investors·2 weeks ago
Protalix Biotherapeutics gains momentum: analysts see long-term upside
Proactive Investors·3 weeks ago
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate
Proactive Investors·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Protalix BioTherapeutics stock?
Protalix BioTherapeutics (PLX) has a market cap of $203M as of April 05, 2025.
What is the P/E ratio for Protalix BioTherapeutics stock?
The price to earnings (P/E) ratio for Protalix BioTherapeutics (PLX) stock is 70.94 as of April 05, 2025.
Does Protalix BioTherapeutics stock pay dividends?
No, Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Protalix BioTherapeutics dividend payment date?
Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protalix BioTherapeutics?
Protalix BioTherapeutics (PLX) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.